In addition, since fusion genes are critical for the development of new diagnoses and new drugs, we selected four fusion genes for testing the isoform expression (Figure 6C,D): CTBS::GNG5, involved in nonneoplastic hematologic disorders in the lymph node and spleen, as well as in epithelial lesions in bladder, skin, and lung [30]; PRIM1::NACA, related to chronic myeloid leukemia [31]; IFNAR2::IL10RB, involved in lung nonneoplastic epithelial disorder [32]; and DNAJC4::NUDT22, related to lung adenocarcinoma [33]. This evidence concerns the gene NACA and chronic myelogenous leukemia, BCR-ABL1 positive.